📈 It supports high-density culture and optimizes cell growth and productivity.
🦠 HEK293 cells are crucial for viral vector production. This medium allows cost-effective scalability for clinical applications.
🔄 It accommodates various transfection methods and processing types, enabling efficient gene therapy development.
Introduction:
This article discusses the recent introduction of BalanCD HEK293 Perfusion A by Fujifilm Biosciences, a specialized cell culture medium designed explicitly for enhanced gene therapy production. The medium is tailored to support the optimal growth and productivity of HEK293 cells, which are commonly utilized in the manufacture of viral vectors for gene therapy applications.
- BalanCD HEK293 Perfusion A is launched to augment gene therapy application solutions, leveraging advanced perfusion technology.
- This medium enables more efficient production processes for viral vectors crucial for gene therapy development, enhancing cell growth, viability, and productivity.
- HEK293 cells exhibit reliable growth rates and high transfection success, crucial for effective gene therapy outcomes.
- The medium supports various transfection methods and is suitable for both steady-state and intensified perfusion processes.
- By enabling capital expenditure reductions, BalanCD HEK293 Perfusion A aims to maximize resources for consistent and scalable production in large-scale clinical settings.
Conclusion:
The introduction of BalanCD HEK293 Perfusion A represents a significant advancement in cell culture media tailored for gene therapy applications, offering opportunities for enhanced process optimization and cost-efficiency. Its compatibility with diverse production systems may facilitate large-scale viral vector production, thereby supporting the continuing evolution of gene therapy as a viable treatment option.
